Delcath Systems, INC 10-Q quarterly reports

Delcath Systems, Inc. announced its second quarter 2026 financial results, showcasing a significant increase in product revenue driven by HEPZATO sales and positive developments in ongoing clinical trials.

Delcath Systems, Inc. reported its first quarter 2026 financial results, showing a significant increase in revenue driven by its HEPZATO KIT product.

Delcath Systems, Inc. announced significant revenue growth and a positive shift to profitability for the nine months ended September 30, 2025, driven by HEPZATO and CHEMOSAT sales and promising clinical trial results.

Delcath Systems, Inc. reported a significant increase in product revenue and a shift to net income for the six months ended June 30, 2025, driven by the commercial expansion of HEPZATO KIT and CHEMOSAT.

Delcath Systems, Inc. reports a significant increase in revenue for Q1 2025, driven by the commercial expansion and demand for its HEPZATO KIT and CHEMOSAT products.

Delcath Systems saw a significant increase in revenue in the third quarter of 2024, primarily due to the commercial launch of its HEPZATO Kit in the U.S.

Delcath Systems saw a significant increase in revenue in the second quarter of 2024, primarily due to the commercial launch of its HEPZATO KIT in the U.S.

Delcath Systems saw a significant increase in revenue in the first quarter of 2024 due to the commercial launch of HEPZATO in the U.S. and increased demand for CHEMOSAT in Europe.